In addition, if it is needed, narrowing -down to patients with EGFR and KRAS mutation-negative adenocarcinomas seems rational, resulting in minimal risk for an inappropriate exclusion of potentially positive patients. This evidence concerns the gene EGFR and adenocarcinoma.